TPD & Induced Proximity Summit Leaderboard
  • Saturday, June 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 17

Author

Pharma Journalist 8887 posts 0 comments

Turning Biophysical Data into Confident Drug Discovery Decisions

Apr 9, 2026
Join the 3rd Biophysics for Drug Discovery Summit – The Countdown Is On! Biophysical methods underpin some of today’s most powerful drug discovery decisions — yet translating physical…
Read More...

Targeted LNP Delivery Beyond the Liver: The Challenges & the Solution

Apr 9, 2026
Join the 5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit As lipid-based therapeutics continue to advance, developers face growing pressure to deliver precise,…
Read More...

The Toxicology Workshop Day Industry Leaders Are Prioritizing Ahead of Investigative &…

Apr 9, 2026
Ahead of the Investigative & Preclinical Toxicology Summit 2026, the dedicated Pre‑Conference Workshop Day is emerging as one of the most highly anticipated elements of the meeting,…
Read More...

RoosterBio Partners MineBio to Expand China Cell Therapy Market

Apr 9, 2026
RoosterBio, Inc. has entered into an exclusive distribution agreement with MineBio Life Sciences Limited to expand access to advanced cell therapy manufacturing solutions across China,…
Read More...

Gilead to Acquire Tubulis, Expanding ADC Cancer Pipeline

Apr 9, 2026
Gilead Sciences, Inc. has announced a definitive agreement to acquire Tubulis GmbH, a clinical-stage biotech firm specializing in next-generation antibody-drug conjugates (ADCs). The…
Read More...

Halozyme, Vertex Partner to Advance Drug Delivery Technology

Apr 9, 2026
Halozyme Therapeutics, Inc. has announced a new global collaboration and licensing agreement with Vertex Pharmaceuticals Incorporated aimed at advancing innovative drug delivery…
Read More...

Sidewinder Therapeutics Secures $137M to Advance Cancer Therapies

Apr 9, 2026
Sidewinder Therapeutics has announced the successful close of an oversubscribed $137 million Series B financing round, marking a significant milestone for the emerging biopharmaceutical…
Read More...

Shionogi Wins U.S. Contract to Advance Fetroja Antibiotic

Apr 8, 2026
Shionogi & Co., Ltd. has secured a major U.S. government contract to expand the development and supply of its antibiotic Fetroja, reinforcing efforts to combat drug-resistant…
Read More...

Alloy, Biogen Partner on Next-Gen Antisense Therapies

Apr 8, 2026
Alloy Therapeutics Inc. has entered into a collaboration and license agreement with Biogen Inc. to advance the development of next-generation antisense therapeutics targeting multiple…
Read More...

Neurocrine to Acquire Soleno in $2.9 Billion Deal

Apr 8, 2026
Neurocrine Biosciences, Inc. has entered into a definitive agreement to acquire Soleno Therapeutics, Inc. in an all-cash transaction valued at approximately $2.9 billion, marking a…
Read More...
Prev Next
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
In Vivo Cell Engineering & Gene Editing Summit
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Voro and Alloy Partner on Safer Cancer Immunotherapies
  • uniQure Reports Early Promise for Epilepsy Gene Therapy
  • Boltz and Takeda Expand AI-Powered Drug Discovery Efforts
  • SK Pharmteco Partners With OTXL for Rare Disease Therapies
  • Next-Generation GLP-1 Therapies Are Reshaping the Future of Obesity Treatment

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.